NASH and the Gut Microbiome: Implications for New Therapies

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2022 Mar 31

PMID 35355843

Authors

Cynthia J Tsay

Joseph K Lim

Affiliations

Soon will be listed here.

Abstract

Content available: Author Audio Recording.

Citing Articles

A Scoping Review on Hepatoprotective Mechanism of Herbal Preparations through Gut Microbiota Modulation.

Poo C, Lau M, Nasir N, Nik Zainuddin N, Rahman M, Mustapha Kamal S Curr Issues Mol Biol. 2024; 46(10):11460-11502.

PMID: 39451562 PMC: 11506797. DOI: 10.3390/cimb46100682.

Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches.

Kakde S, Mushtaq M, Liaqat M, Ali H, Mushtaq M, Sarwer M Cureus. 2024; 16(9):e69129.

PMID: 39398771 PMC: 11467241. DOI: 10.7759/cureus.69129.

Development of non-alcoholic steatohepatitis is associated with gut microbiota but not with oxysterol enzymes CH25H, EBI2, or CYP7B1 in mice.

Wyss J, Raselli T, Wyss A, Telzerow A, Rogler G, Krupka N BMC Microbiol. 2024; 24(1):69.

PMID: 38418983 PMC: 10900623. DOI: 10.1186/s12866-024-03195-7.

The Role of in Liver Diseases: A Systematic Review of Next-Generation Sequencing Studies.

Hizo G, Rampelotto P Microorganisms. 2023; 11(12).

PMID: 38138143 PMC: 10745637. DOI: 10.3390/microorganisms11122999.

Gut Microbiome in the Progression of NAFLD, NASH and Cirrhosis, and Its Connection with Biotics: A Bibliometric Study Using Dimensions Scientific Research Database.

Pezzino S, Sofia M, Mazzone C, Castorina S, Puleo S, Barchitta M Biology (Basel). 2023; 12(5).

PMID: 37237476 PMC: 10215374. DOI: 10.3390/biology12050662.

References

Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M . Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017; 117(5):662-668. DOI: 10.1017/S0007114517000204. View

Meroni M, Longo M, Dongiovanni P . The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019; 11(11). PMC: 6893730. DOI: 10.3390/nu11112642. View

Mouzaki M, Comelli E, Arendt B, Bonengel J, Fung S, Fischer S . Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013; 58(1):120-7. DOI: 10.1002/hep.26319. View

Said A, Akhter A . Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis. Ann Hepatol. 2017; 16(4):538-547. DOI: 10.5604/01.3001.0010.0284. View

Ma J, Zhou Q, Li H . Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients. 2017; 9(10). PMC: 5691740. DOI: 10.3390/nu9101124. View

Zhu L, Baker S, Gill C, Liu W, Alkhouri R, Baker R . Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2012; 57(2):601-9. DOI: 10.1002/hep.26093. View

Tarantino G, Finelli C . Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol. 2015; 10(5):889-902. DOI: 10.2217/fmb.15.13. View

Mehal W, Loomba R . The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic Steatosis. Hepatology. 2019; 70(2):741-744. PMC: 6984973. DOI: 10.1002/hep.30577. View

Singh S, Khera R, Allen A, Murad M, Loomba R . Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology. 2015; 62(5):1417-32. DOI: 10.1002/hep.27999. View

10.

Vrieze A, van Nood E, Holleman F, Salojarvi J, Kootte R, Bartelsman J . Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012; 143(4):913-6.e7. DOI: 10.1053/j.gastro.2012.06.031. View

11.

Kootte R, Levin E, Salojarvi J, Smits L, Hartstra A, Udayappan S . Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab. 2017; 26(4):611-619.e6. DOI: 10.1016/j.cmet.2017.09.008. View

12.

Kiziltas S . Toll-like receptors in pathophysiology of liver diseases. World J Hepatol. 2016; 8(32):1354-1369. PMC: 5114472. DOI: 10.4254/wjh.v8.i32.1354. View

13.

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

14.

Jiang C, Xie C, Li F, Zhang L, Nichols R, Krausz K . Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2014; 125(1):386-402. PMC: 4382255. DOI: 10.1172/JCI76738. View

15.

Safari Z, Gerard P . The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci. 2019; 76(8):1541-1558. PMC: 11105223. DOI: 10.1007/s00018-019-03011-w. View

16.

Mouzaki M, Loomba R . An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment. Curr Treat Options Gastroenterol. 2021; 18(2):270-280. PMC: 7946055. DOI: 10.1007/s11938-020-00290-2. View

17.

Henao-Mejia J, Elinav E, Thaiss C, Licona-Limon P, Flavell R . Role of the intestinal microbiome in liver disease. J Autoimmun. 2013; 46:66-73. DOI: 10.1016/j.jaut.2013.07.001. View

18.

Kolodziejczyk A, Zheng D, Shibolet O, Elinav E . The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2018; 11(2). PMC: 6365925. DOI: 10.15252/emmm.201809302. View

19.

Suk K, Kim D . Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019; 13(3):193-204. DOI: 10.1080/17474124.2019.1569513. View

20.

Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R . Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2011; 57(2):545-53. DOI: 10.1007/s10620-011-1887-4. View